These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Simultaneous measurement of acalabrutinib, ibrutinib, and their metabolites in beagle dog plasma by UPLC-MS/MS and its application to a pharmacokinetic study.
    Author: Jiang Z, Shi L, Zhang Y, Lin G, Wang Y.
    Journal: J Pharm Biomed Anal; 2020 Nov 30; 191():113613. PubMed ID: 32971496.
    Abstract:
    In our present experiment, the aim of this paper was to develop and fully validate an accurate and simple ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) assay for simultaneous quantification of acalabrutinib, ibrutinib, and their metabolites (ACP-5862 and PCI-45227) in beagle dog plasma and to survey the pharmacokinetic study of all analytes in beagle dogs. After a quick protein precipitation with acetonitrile, the chromatographic separation of acalabrutinib, ACP-5862, ibrutinib, PCI-45227 and bosutinib (internal standard, IS) were finished on an Acquity BEH C18 (2.1 mm × 50 mm, 1.7 μm) column and their detections were conducted by a Xevo TQ-S triple quadrupole tandem mass spectrometer in the positive ion mode. The assay displayed excellent linearity in the calibration range of 0.5-300 ng/mL for acalabrutinib, 0.5-30 ng/mL for ACP-5862, and 0.5-200 ng/mL for both ibrutinib and PCI-45227, respectively. Notably, the lower limit of quantification (LLOQ) for each compound was determined to be 0.5 ng/mL. The accuracy of all analytes for intra- and inter-day ranged from -4.3% to 14.6%, while precision were ≤9.0%. The recovery of each substance was > 81.0%, and no significant matrix effects were observed. The stabilities of all analytes under different conditions met all requirements for the quantitation in plasma samples. In addition, our developed UPLC-MS/MS method could also be employed to measure the pharmacokinetic profiles of acalabrutinib, ACP-5862, ibrutinib, and PCI-45227 in beagle dog plasma.
    [Abstract] [Full Text] [Related] [New Search]